Infertility is a frequent problem affecting up to 26% of all couples globally. Impaired semen quality is responsible for approximately 50% of all cases, but no treatment options exist. This current study provides insights into a yet unrecognized regulatory role of RANKL in male reproductive function.
Infertile men have few treatment options. Here, we demonstrate that the transmembrane receptor activator of NF-kB ligand (RANKL) signaling system is active in mouse and human testis. RANKL is highly expressed in Sertoli cells and signals through RANK, expressed in most germ cells, whereas the RANKL-inhibitor osteoprotegerin (OPG) is expressed in germ and peritubular cells. OPG treatment increases wild-type mouse sperm counts, and mice with global or Sertoli-specific genetic suppression of Rankl have increased male fertility and sperm counts. Moreover, RANKL levels in seminal fluid are high and distinguishes normal from infertile men with higher specificity than total sperm count. In infertile men, one dose of Denosumab decreases RANKL seminal fluid concentration and increases serum Inhibin-B and anti-Müllerian-hormone levels, but semen quality only in a subgroup. This translational study suggests that RANKL is a regulator of male reproductive function, however, predictive biomarkers for treatment-outcome requires further investigation in placebo-controlled studies.
Find the full text here.
Eagle Biosciences offers an ELISA kit that can measure soluble RANKL and OPG in serum and seminal fluid. These kits are reliable and highly sensitive. For more information about these kits or our other offerings, contact us here.